115 proteins identified that would allow designing new generation anti-cancer drugs

For this reason it is important to develop multi-target drugs, meaning drugs that are able to attack several targets simultaneously, that are more effective and with fewer side effects

One of the key aspects of the research in new cancer drugs is determining with what proteins the drug should interact, so as to destroy the tumour cells without affecting healthy ones. In this sense, the work presents a new strategy to identify proteins that are highly relevant in cancer.

According to Jordi Mestres, the coordinator of the Chemogenomics Laboratory of the GRIB "The basis of this strategy is a list of molecules that, experimentally, have been proven to be significantly more toxic for tumour cells than for healthy ones and another list of molecules that are more toxic for healthy cells than for tumour ones. These two lists of molecules are computationally processed with a methodology that allows predicting those proteins for which each molecule will have an affinity, identifying potential biological targets to develop new anti-cancer drugs."

The researchers' contributions have been, more specifically, the prediction of proteins that interact with molecules that have experimentally shown a differential cytotoxicity, either for tumour cells or healthy ones. The larges efforts were made in experimental testing of 30,000 molecules and the logistical difficulty this entails. Overall, 119,520 cytotoxicity data were generated for both tumour and healthy cells. Once both groups of molecules with the highest differential cytotoxicity were identified, predicting those proteins with which they interacted was very effective thanks to a methodology that was originally developed by the same researchers participating in the study which then became the foundation of the Chemotargets spin-off.

This study is part of the doctoral theses of students Praveena Kuchipudi and Nikita Remez, from the GRIB, with the collaboration of Prof. Ferran Sanz, the director of the GRIB. It is framed within a project of the 6th European Framework Programme CancerGrid , and was lead by the Hungarian company AMRI, that contributed its compound library (a collection of millions of compounds), and by testing them it was possible to identify molecules with a differential cytotoxicity.